Relman David A
Department of Microbiology and Immunology, Stanford University, Stanford, California, USA.
J Infect Dis. 2002 Dec 1;186 Suppl 2:S254-8. doi: 10.1086/344935.
Evidence suggests that a significant number of clinically important microbial pathogens remain unrecognized. Observations from the natural world, from patterns of disease in human populations, from the bedside, and from the clinical laboratory all contribute to this body of evidence. A variety of acute and chronic neurologic syndromes illustrate this point; despite features of infection, most cases of aseptic meningitis, encephalitis, and cerebral vasculitis cannot be assigned a microbiologic diagnosis. The development and clinical application of molecular methods have led to the discovery of novel members of the endogenous normal flora as well as putative disease agents. Current challenges include the establishment of criteria for disease causation and further characterization of the human microbiome during states of health. These challenges and the goal of understanding microbial contributions to inflammatory disease may be addressed effectively through the thoughtful integration of modern technologies and clinical insight.
有证据表明,大量具有临床重要性的微生物病原体仍未被识别。来自自然界的观察、人群疾病模式、床边观察以及临床实验室的观察都为这一证据体系做出了贡献。多种急性和慢性神经综合征都说明了这一点;尽管有感染的特征,但大多数无菌性脑膜炎、脑炎和脑血管炎病例都无法做出微生物学诊断。分子方法的发展和临床应用导致了内源性正常菌群新成员以及假定病原体的发现。当前的挑战包括确立疾病因果关系的标准以及在健康状态下进一步表征人类微生物组。通过对现代技术和临床洞察力进行深思熟虑的整合,可以有效应对这些挑战以及理解微生物对炎症性疾病影响的目标。